Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis

Cargnin, Sarah; Canonico, Pier Luigi; Genazzani, Armando A.; Terrazzino, Salvatore

doi:10.1016/j.jtho.2016.08.002

Cited by 34 publications

(35 citation statements)

References 39 publications

(210 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While cfDNA is more frequently thought of as a means for identifying therapeutically targetable driver and resistance mutations, we and others have also shown that measuring the amount of cfDNA in plasma can be prognostic (Cargnin et al., ; Thompson et al., ). This may be especially relevant for our cohort of heavily pretreated patients, for whom mutations were detected in 12 of 25 plasma samples, but cfDNA yield was quantifiable for all 25 patients.…”

Section: Discussionmentioning

confidence: 95%

“…Cell-free DNA concentration, independent of the identification of specific mutations, has also been shown to have prognostic value (Cargnin, Canonico, Genazzani, & Terrazzino, 2017;Thompson et al, 2016), although this has not yet been measured in melanoma. Plasma cfDNA yields for patients with lung and breast cancer have been associated with a worse prognosis (Couraud et al, 2014;Dawson et al, 2013;Thompson et al, 2016), and changes in cfDNA levels can precede clinical and radiographic tumor regression or progression, thus allowing for real-time, non-invasive surveillance of tumor burden (Lipson et al, 2014).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Feasibility of monitoring advanced melanoma patients using cell‐free DNA from plasma

Gangadhar

Savitch

Yee

et al. 2017

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

mentioning

confidence: 99%

Feasibility of monitoring advanced melanoma patients using cell‐free DNA from plasma

Gangadhar

Savitch

Yee

et al. 2017

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

show abstract

“…Therefore, there has been an explosion of technologies for the quantification and analysis of both these markers from the non-invasive and highly accessible “liquid biopsies”, however there is still a lack of standardization [55,56,59]. Quantification and integrity index of cfDNA are still proved to be valid diagnostic and prognostic markers in human cancer [23,43–47,60]. However, enormous improvement in sensitivity and specificity of downstream analysis has been achieved for example by next generation sequencing (NGS), digital droplet PCR (ddPCR), and beads, emulsion, amplification, magnetics (BEAMing) PCR for tumor association, mutational analysis, and patient monitoring [55,61].…”

Section: Discussionmentioning

confidence: 99%

Circulating Cell-Free DNA in Dogs with Mammary Tumors: Short and Long Fragments and Integrity Index

et al. 2017

View full text Add to dashboard Cite

Circulating cell-free DNA (cfDNA) has been considered an interesting diagnostic/prognostic plasma biomarker in tumor-bearing subjects. In cancer patients, cfDNA can hypothetically derive from tumor necrosis/apoptosis, lysed circulating cells, and some yet unrevealed mechanisms of active release. This study aimed to preliminarily analyze cfDNA in dogs with canine mammary tumors (CMTs). Forty-four neoplastic, 17 non-neoplastic disease-bearing, and 15 healthy dogs were recruited. Necrosis and apoptosis were also assessed as potential source of cfDNA on 78 CMTs diagnosed from the 44 dogs. The cfDNA fragments and integrity index significantly differentiated neoplastic versus non-neoplastic dogs (P<0.05), and allowed the distinction between benign and malignant lesions (P<0.05). Even if without statistical significance, the amount of cfDNA was also affected by tumor necrosis and correlated with tumor size and apoptotic markers expression. A significant (P<0.01) increase of Bcl-2 in malignant tumors was observed, and in metastatic CMTs the evasion of apoptosis was also suggested. This study, therefore, provides evidence that cfDNA could be a diagnostic marker in dogs carrying mammary nodules suggesting that its potential application in early diagnostic procedures should be further investigated.

show abstract

“…A higher baseline cfDNA concentration correlated with a statistically significant increase in the risk of death (HR 1.76, P<0.001). They were not, however, able to reach consensus on a cfDNA concentration cutoff point that portends a higher risk of poor outcomes given the heterogeneity of tests and reference genes that were used to detect the ctDNA (38).…”

Section: Prognostic Value Of Ctdna Concentrationsmentioning

confidence: 99%

Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer

Marmarelis¹,

Thompson²,

Aggarwal³

et al. 2017

Ann. Transl. Med.

View full text Add to dashboard Cite

Targeted therapies have dramatically changed the treatment paradigm for a select group of patients with non-small cell lung cancer (NSCLC) whose tumors harbor targetable genetic aberrations.Patients with such genetic changes enjoy excellent responses to tyrosine kinase inhibitors (TKIs), but resistance is nearly inevitable. Resistance to first line TKIs is heterogeneous and multifactorial-multiple resistance mechanisms have been reported, and different metastatic foci in the same patient may have distinct resistance mechanisms. The recent approval of next-generation TKIs specific to particular resistance mechanisms, and the likely future approval of others, necessitates the acquisition of repeat molecular analysis at time of progression. Tumor tissue has traditionally been the preferred source to detect oncogenic driver and resistance mutations, but tissue biopsies are invasive and often difficult to obtain. The use of circulating tumor DNA (ctDNA), so-called "liquid biopsies", has emerged as a promising technique to molecularly profile tumors non-invasively and is becoming increasingly utilized in the routine management of lung cancer. This review will describe the current role of ctDNA in the management of lung cancer, and explore emerging data that point towards its increasingly important role in clinical care.

show abstract

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis

Cited by 34 publications

References 39 publications

Feasibility of monitoring advanced melanoma patients using cell‐free DNA from plasma

Feasibility of monitoring advanced melanoma patients using cell‐free DNA from plasma

Circulating Cell-Free DNA in Dogs with Mammary Tumors: Short and Long Fragments and Integrity Index

Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer

Contact Info

Product

Resources

About